Skip to main content

Posts tagged with "Current Events"

  • Clinical Trials

    Anti IL-6 For Coronavirus Patients: Does It Work, or Not?

    It’s been looking for some time as if these coronavirus infections need a biphasic approach to therapy – an antiviral approach earlier on, and for those in serious trouble, perhaps a shift to immune modulation as the body’s reaction to the virus starts doing even more harm. That post goes into some detail on possible… Read More
  • Covid-19

    A Close Look at the Frontrunning Coronavirus Vaccines As of May 1 (updated)

    There’s plenty of news on the coronavirus vaccine front, so let’s have a look. If you need some details on the different sorts of vaccines in general, here’s the background post, which should help this one make sense. This is a rapidly advancing field, with a huge number of programs. Some of the players are… Read More
  • Current Events

    The Politics of Hydroxychloroquine

    I had not been planning to return to the topic of hydroxychloroquine so soon, but here we are. This will not be a calm, measured blog post – fair warning. Yesterday, Dr. Rick Bright was pushed out of his post at HHS, where he was deputy assistant secretary for preparedness and response and director of BARDA… Read More
  • Biological News

    Watching For Mutations in the Coronavirus

    The coronavirus outbreak has been accompanied by a huge amount of sequencing data, as well it should be. is a great place to see this in action: region by region, the spread of the infection can be tracked, often with enough detail to say where the virus must have come in from and how… Read More
  • Clinical Trials

    What’s Happening With Remdesivir?

    Well, everyone was just dealing with the news that Gilead’s antiviral remdesivir had had two trials suspended in China, when Stat‘s Adam Feuerstein and Matthew Herper broke news last night about a trial here in the US. 125 patients had been recruited at the University of Chicago to receive daily doses of remdesivir, and the… Read More
  • Clinical Trials

    Coronavirus Vaccine Prospects

    Time for another look at the coronavirus vaccine front, since we have several recent news items. Word has come from GSK and Sanofi that they are going to collaborate on vaccine development, which brings together two of the more experienced large organizations in the field. It looks like Sanofi is bringing the spike protein and… Read More
  • Current Events

    Omeprazole As An Additive For Coronavirus Therapy

    One of the notable things about the current pandemic is the way that all our modern biology and analytical techniques are on display. Molecular biology, structural biology, bioinformatics, technologies like cryo-EM structure determination, fast sequencing, protein interaction screening and more – this is a real-time look at how basic biomedic… Read More
  • Cardiovascular Disease

    The Latest Hydroxychloroquine Data, As of April 11

    We have new data on hydroxychloroquine therapy to discuss. The numbers will not clear anything up. First off is an abstract from the Marseilles IHU group of Dr. Didier Raoult. It presents 1061 patients treated for at least 3 days with their hydroxychloroquine/azithromycin combination, with followup of at least 9 days. It includes the statement… Read More
  • Current Events

    What Do the New Remdesivir Data Mean?

    A report has come out in the NEJM on the experience with “compassionate use” (off-label or not yet approved) of the Gilead drug remdesivir in the Covid-19 epidemic. Here are the inclusion criteria: Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air… Read More
  • Analytical Chemistry

    More on Screening For Coronavirus Therapies

    Time for a word about screening for new coronavirus drugs. Things have gone on long enough for quite a few groups to produce supplies of the various viral proteins and set up small-molecule screens against them. That’s no bad thing in itself, although it is a slow thing, a very slow thing by the standards… Read More